Hepatitis C
EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 22 April 2017 00:00
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress this week in Amsterdam.
EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- Details
- Category: HCV Treatment
- Published on Friday, 21 April 2017 00:00
Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at that young age, according to a presentation at the at the EASL International Liver Congress this week in Amsterdam.
EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- Details
- Category: HCV Disease Progression
- Published on Thursday, 20 April 2017 00:00
Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.
EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 April 2017 00:00
AbbVie's pangenotypic direct-acting antiviral combination of 2 drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV) infection, the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the EASL International Liver Congress this week in Amsterdam.
CROI 2017: Hepatitis C Treatment Can Be Provided Successfully at Syringe Exchange Sites
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 13 April 2017 00:00
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Expanding treatment for this population could reduce hepatitis C virus (HCV) transmission and ultimately help eliminate hepatitis C as a public health threat.
EASL 2017: Curing Hepatitis C Reduces Cardiovascular Risk
- Details
- Category: HCV-Related Conditions
- Published on Friday, 21 April 2017 00:00
Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, according to a large French study presented this week at the International Liver Congress in Amsterdam.
BHIVA 2017: London Data Shows Hepatitis C Is Transmitted During Anal Sex Without Condoms
- Details
- Category: Gay & Bisexual Men/MSM
- Published on Thursday, 13 April 2017 00:00
Around 1 in 5 HIV-positive gay men who recently acquired hepatitis C virus (HCV) report anal sex without a condom as the only behavior that could explain their infection. At the same time, a third of people acquiring HCV were gay men who did not have HIV, clinicians from the Mortimer Market Centre in London reported at the British HIV Association (BHIVA) conference last week in Liverpool. The data suggest that prevention messages around sexually transmitted hepatitis C need to change.
EASL 2017: European HCV Treatment Access Survey Shows Big Variations in Eligibility
- Details
- Category: HCV Policy & Advocacy
- Published on Friday, 21 April 2017 00:00
England, Malta, Slovakia, Hungary, and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland, and the Netherlands are the least restrictive, according to research presented at the International Liver Congress this week in in Amsterdam, the annual meeting of the European Association for the Study of the Liver (EASL).
FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C
- Details
- Category: Approved HCV Drugs
- Published on Saturday, 08 April 2017 00:00
The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years. Sofosbuvir/ledipasvir (Harvoni) is now indicated for adolescents with HCV genotypes 1, 4, 5, or 6, while sofosbuvir (Sovaldi) plus ribavirin is approved for those with genotypes 2 or 3.
More Articles...
- CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands
- CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- Coverage of the 2016 AASLD Liver Meeting
- AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
Web Design and Development by